Alliance Global Partners Cuts InspireMD (NYSEAMERICAN:NSPR) Price Target to $5.25

InspireMD (NYSEAMERICAN:NSPR – Get Rating) had its price objective lowered by Alliance Global Partners from $9.00 to $5.25 in a research report released on Wednesday morning, The Fly reports.

NSPR opened at $2.08 on Wednesday. The company has a market capitalization of $17.31 million, a PE ratio of -0.69 and a beta of 1.51. InspireMD has a 52 week low of $1.91 and a 52 week high of $6.82.

InspireMD (NYSEAMERICAN:NSPR – Get Rating) last released its earnings results on Tuesday, May 10th. The medical equipment provider reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.23. InspireMD had a negative return on equity of 43.80% and a negative net margin of 448.33%.

A number of hedge funds have recently bought and sold shares of the stock. HighTower Advisors LLC increased its position in InspireMD by 60.4% during the 4th quarter. HighTower Advisors LLC now owns 26,567 shares of the medical equipment provider’s stock valued at $81,000 after buying an additional 10,000 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in InspireMD during the 2nd quarter valued at approximately $85,000. Geode Capital Management LLC bought a new position in InspireMD during the 3rd quarter valued at approximately $57,000. Finally, Avestar Capital LLC bought a new stake in shares of InspireMD in the 4th quarter worth $30,000. 2.09% of the stock is owned by institutional investors.

About InspireMD (Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Featured Articles